Investment Thesis
UTHR demonstrates exceptional fundamental strength with 82.9% gross margins, 41.7% operating margins, and remarkable 46.4% free cash flow margin. The company combines solid 10.6% revenue growth with faster 13.1% EPS growth, indicating improving per-share economics, while maintaining a fortress balance sheet with zero debt and $1.3B cash, demonstrating financial resilience in a competitive pharma sector.
Strengths
- Exceptional profitability margins across all levels (gross, operating, net) indicating strong pricing power and operational efficiency
- Robust free cash flow generation of $362.5M (46.4% margin) provides financial flexibility for R&D and shareholder returns
- Zero long-term debt with $1.3B cash and 4.79x current ratio, offering significant downside protection and strategic optionality
- EPS growth (13.1%) outpacing revenue growth (10.6%) indicates improving operational leverage and per-share value creation
- Strong balance sheet with $5.9B equity, minimizing financial risk
Risks
- Pharmaceutical sector exposure to patent expirations, regulatory changes, and drug development pipeline risks
- Relatively low ROE (4.7%) and ROA (4.1%) suggest capital may not be deployed at optimal returns despite margin excellence
- Significant insider activity (75 Form 4 filings in 90 days) warrants monitoring for potential selling pressure
- Moderate revenue growth rate of 10.6% YoY may face pressure from competitive dynamics or market saturation
Key Metrics to Watch
- Free cash flow sustainability and margin trajectory as revenue scales
- Revenue growth acceleration and product pipeline success rates
- Return on equity improvement trajectory and capital efficiency metrics
- Operating margin maintenance under pricing pressure or cost inflation scenarios
Financial Metrics
Revenue
781.5M
Net Income
274.9M
EPS (Diluted)
$5.82
Free Cash Flow
362.5M
Total Assets
6.7B
Cash
1.3B
Profitability Ratios
Gross Margin
82.9%
Operating Margin
41.7%
Net Margin
35.2%
ROE
4.7%
ROA
4.1%
FCF Margin
46.4%
Balance Sheet & Liquidity
Current Ratio
4.79x
Quick Ratio
4.50x
Debt/Equity
0.00x
Debt/Assets
12.1%
Interest Coverage
24.50x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T16:37:52.000058 |
Data as of: 2026-03-31 |
Powered by Claude AI